News

Filter

Current filters:

PfizerRare diseases

1 to 9 of 39 results

FDA approves Elelyso for pediatric use in Gaucher disease

FDA approves Elelyso for pediatric use in Gaucher disease

29-08-2014

The US Food and Drug Administration has approved US pharma giant Pfizer’s Elelyso (taliglucerase alfa)…

ElelysoPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationUSA

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Negative NICE appraisal of Pfizer’s Bosulif for CML

Negative NICE appraisal of Pfizer’s Bosulif for CML

27-11-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRare diseasesRegulation

Repligen gets first milestone under SMA deal with Pfizer

05-09-2013

USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

Protalix BioTherapeutics enters Gaucher drug Uplyso deal with Brazil's Ministry of Health

19-06-2013

Israel-based Protalix BioTherapeutics (TASE:PLX) has entered into a supply and technology transfer agreement…

FiocruzMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesSouth AmericaUplyso

Pfizer and Protalix' Gaucher drug Uplyso approved in Brazil

19-03-2013

US drugs behemoth Pfizer (NYSE: PFE) and Israel-based Protalix BioTherapeutics (NYSE MKT:PLX) said that…

BiotechnologyElelysoPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationSouth AmericaUplyso

Repligen in $70 million deal with Pfizer for SMA program

04-01-2013

USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

1 to 9 of 39 results

COMPANY SPOTLIGHT

Menarini

Back to top